🚀 VC round data is live in beta, check it out!
Alvotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alvotech and similar public comparables like Jade Biosciences, Aktis Oncology, Neuren Pharma, GH Research and more.
Alvotech Overview
About Alvotech
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Founded
2018
HQ
Employees
1.1K
Website
Sectors
Financials (LTM)
EV
$2B
Alvotech Financials
Alvotech reported last 12-month revenue of $600M and EBITDA of $152M.
In the same LTM period, Alvotech generated $362M in gross profit, $152M in EBITDA, and $119M in net income.
Revenue (LTM)
Alvotech P&L
In the most recent fiscal year, Alvotech reported revenue of $593M and EBITDA of $311M.
Alvotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $600M | XXX | $593M | XXX | XXX | XXX |
| Gross Profit | $362M | XXX | $351M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $152M | XXX | $311M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 52% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $119M | XXX | $158M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alvotech Stock Performance
Alvotech has current market cap of $1B, and enterprise value of $2B.
Market Cap Evolution
Alvotech's stock price is $3.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $1B | -0.7% | XXX | XXX | XXX | $0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlvotech Valuation Multiples
Alvotech trades at 4.0x EV/Revenue multiple, and 15.8x EV/EBITDA.
EV / Revenue (LTM)
Alvotech Financial Valuation Multiples
As of April 18, 2026, Alvotech has market cap of $1B and EV of $2B.
Equity research analysts estimate Alvotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alvotech has a P/E ratio of 9.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.0x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.8x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBIT | 21.7x | XXX | 24.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.6x | XXX | 6.8x | XXX | XXX | XXX |
| P/E | 9.4x | XXX | 7.1x | XXX | XXX | XXX |
| EV/FCF | (32.9x) | XXX | (20.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alvotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alvotech Margins & Growth Rates
Alvotech's revenue in the last 12 month grew by 10%.
Alvotech's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Alvotech's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alvotech's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alvotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 52% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | (40%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 32% | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alvotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alvotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Jade Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Aktis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Neuren Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| GH Research | XXX | XXX | XXX | XXX | XXX | XXX |
| Collegium Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alvotech M&A Activity
Alvotech acquired XXX companies to date.
Last acquisition by Alvotech was on XXXXXXXX, XXXXX. Alvotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alvotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlvotech Investment Activity
Alvotech invested in XXX companies to date.
Alvotech made its latest investment on XXXXXXXX, XXXXX. Alvotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alvotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alvotech
| When was Alvotech founded? | Alvotech was founded in 2018. |
| Where is Alvotech headquartered? | Alvotech is headquartered in United States. |
| How many employees does Alvotech have? | As of today, Alvotech has over 1K employees. |
| Who is the CEO of Alvotech? | Alvotech's CEO is Robert Wessman. |
| Is Alvotech publicly listed? | Yes, Alvotech is a public company listed on Nasdaq. |
| What is the stock symbol of Alvotech? | Alvotech trades under ALVO ticker. |
| When did Alvotech go public? | Alvotech went public in 2022. |
| Who are competitors of Alvotech? | Alvotech main competitors are Jade Biosciences, Aktis Oncology, Neuren Pharma, GH Research. |
| What is the current market cap of Alvotech? | Alvotech's current market cap is $1B. |
| What is the current revenue of Alvotech? | Alvotech's last 12 months revenue is $600M. |
| What is the current revenue growth of Alvotech? | Alvotech revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Alvotech? | Current revenue multiple of Alvotech is 4.0x. |
| Is Alvotech profitable? | Yes, Alvotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alvotech? | Alvotech's last 12 months EBITDA is $152M. |
| What is Alvotech's EBITDA margin? | Alvotech's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Alvotech? | Current EBITDA multiple of Alvotech is 15.8x. |
| What is the current FCF of Alvotech? | Alvotech's last 12 months FCF is ($73M). |
| What is Alvotech's FCF margin? | Alvotech's last 12 months FCF margin is (12%). |
| What is the current EV/FCF multiple of Alvotech? | Current FCF multiple of Alvotech is (32.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.